Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million
04 déc. 2023 09h15 HE
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a commercial-stage developer of wearable products for pain relief, general wellness, and wound curatives...
Endonovo Targets Dept. of Defense, VA & Federal Contracts
03 janv. 2023 09h09 HE
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced the advancement of its aggressive “Go to Market” strategy for expansion of SofPulse® medical...
Endonovo Launches Telehealth Initiative
13 déc. 2022 09h11 HE
|
Endonovo Therapeutics, Inc.
Expands Patient Education, Access to Non-Opioid Options for Pain Management Los Angeles, CA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the...
Endonovo Therapeutics Issues Corporate Update
07 nov. 2022 09h07 HE
|
Endonovo Therapeutics, Inc.
Highlights its previously-announced “Build Up Strategy” of acquiring complementary specialty service providers in the construction industry Los Angeles, CA, Nov. 07, 2022 (GLOBE NEWSWIRE) --...
$5 Million Common Stock Offering for Endonovo Therapeutics Designed to Advance SofPulse® Process for Medical Reimbursement
11 avr. 2022 09h08 HE
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, April 11, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced significant advancement in the of process to obtain medical reimbursements for its...